precise
Posted - 4 days ago
@wjmax @thompske @FE123 Yep, I think $ELEV is going to be the next ADC acquisition target
ViractaTrader77
Posted - 5 days ago
$BDTX $CRBP Sutro Bio has almost $6 in current assets in cash per share. Big deals with Merck, Vaxcyte, Ispen Pharma and Astellas. And a similar ADC company targeting Folate Receptor with earlier asset just got bought for $1.8 billion. It's the second acquisition in folate receptor first one was Immunogen. Steve Cohen and Ispen Pharma just invested heavily at $5.18 per share. $ELEV $NVDA https://x.com/SutroBio/status/1775949657774112893
StardustTrader
Posted - 6 days ago
$GRTS looks like we're taking the route of $ELEV . Gonna have to be patient
Peterpaypaul
Posted - 6 days ago
$ELEV Very nice Institutional accumulation, this is right on time..... 😊
azh90
Posted - 6 days ago
$elev
Why volume very tiny low
precise
Posted - 6 days ago
$ELEV Smart money is really piling in here. I think bc theres already clinical proof outside of US and they have a grip on US
RonIsWrong
Posted - 1 week ago
$ELEV FRAZIER LIFE SCIENCES PUBLIC FUND, L.P. new position 2.9M shares (12%)
WallStArb
Posted - 1 week ago
@ViractaTrader77 they were hot - they are. Oolong off and raising cash - looks like the ADC hype has served it purpose and new bag holders at 500% - 1000% moves since December are rear view - best of luck $ADCT $VINC $ELEV $MRSN etc
WallStArb
Posted - 1 week ago
$VINC reminds me of $ELEV last year after it announced the PIPE and traded from $5 to $0.35 over 6 months - wouldn’t touch this
RainbowTrump
Posted - 1 week ago
$ELEV is there legit no movement here?
DonCorleone77
Posted - 1 week ago
$ELEV 3 of 3 - Elevation Oncology presents preclinical proof-of concept data for HER3-ADC ....In cytotoxicity assays, HER3-ADC1 displayed HER3-dependent cell killing and outperformed a benchmark HER3-ADC with a deruxtecan payload, which is currently in clinical development. In a patient derived xenograft model of pancreatic cancer with high HER3 expression, HER3-ADC1 induced tumor regression, whereas an isotype-MMAE control and a benchmark HER3-ADC with a deruxtecan payload had only a modest effect.
DonCorleone77
Posted - 1 week ago
$ELEV 2 of 3 - Elevation Oncology presents preclinical proof-of concept data for HER3-ADC ....and robust anti-tumor activity in vivo where HER3 is expressed at high levels. We look forward to nominating a development candidate from our HER3 program later this year and, subsequently, advancing our program closer to the clinic." In a poster titled, "Therapeutic potential of a HER3 antibody-drug conjugate for the treatment of HER3-expressing cancers," Elevation Oncology scientists presented in vitro and in vivo data of a seribantumab-based ADC for patients with HER3-expressing cancers. The data showed: HER3-ADC1 binding to cancer cells, endocytosis, MMAE release and inhibition of proliferation were dependent on HER3 expression....
DonCorleone77
Posted - 1 week ago
$ELEV 1 of 3 - Elevation Oncology presents preclinical proof-of concept data for HER3-ADC Elevation Oncology announced new preclinical data demonstrating proof-of-concept for its differentiated HER3-ADC program. The data will be presented in a poster session at the American Association for Cancer Research Annual Meeting 2024, being held April 5-10 in San Diego, California. "We are pleased to share the first preclinical proof-of-concept data for our HER3-ADC program, reinforcing our commitment to advancing a portfolio of differentiated ADC-based therapies that may deliver better outcomes for patients," said David Dornan, Ph.D., Chief Scientific Officer of Elevation Oncology. "With our HER3-ADC program, we set out to design a differentiated ADC which selectively binds to HER3 and is internalized to potentially attack HER3-expressing cancerous cells while minimizing systemic exposure. Preclinical data with our proof-of-concept HER3-ADC shows HER3-dependent cell killing....
Stock_Titan
Posted - 1 week ago
$ELEV Elevation Oncology Presents Preclinical Proof-of-Concept Data for HER3-ADC Program at AACR Annual Meeting 2024
https://www.stocktitan.net/news/ELEV/elevation-oncology-presents-preclinical-proof-of-concept-data-for-1bcvtshu3btt.html
ViractaTrader77
Posted - 1 week ago
$STRO Trading at cash in hottest sector in biotech.
Antibody Drug Conjugates
Deals with Ispen Pharma and Astellas
(Ambrx had deal with Astellas as well they just got acquired for $2 billion) sl
Sutro worth $8.50 minimum
biotech value fund in large
$PYXS $ADCT $ELEV
M0ses
Posted - 2 weeks ago
$ELEV After hours rip! Load it.
M0ses
Posted - 2 weeks ago
$ELEV Well that was interesting to watch! Try again tomorrow?
never_gonna_quit
Posted - 2 weeks ago
$ELEV time to rip face
FonsieTrader
Posted - 2 weeks ago
$ELEV Its setting up to be next $ABIO $KTRA $VNDA or $ACB
RonIsWrong
Posted - 2 weeks ago
$ELEV Watching Elevation Oncology; Traders Circulate M&A Blog Comments Saying 'The Intensity Of M&A Interest Among ADC Developers As Well As A Transactional ELEV Management Team Have Made This Company Hard To Ignore' --BENZINGA ADCs have been hot as hell, with *another* acquisition today.
precise
Posted - 2 weeks ago
@ViractaTrader77 I prefer $ELEV but they are quite similar
ViractaTrader77
Posted - 2 weeks ago
$STRO $17 price target for this ADC maker.
Trading at cash value $ELEV $BDTX $LVTX
RonIsWrong
Posted - 2 weeks ago
$ELEV 2.9M share dark pool trade today
precise
Posted - 2 weeks ago
$ELEV In at $5 with a very small position. Claudin 18.2 is a very high probability of success target. Will add dips!
Peterpaypaul
Posted - 2 weeks ago
$ELEV We are excited to share preclinical proof-of-concept data for our HER3-ADC program. HER3 is a clinically validated oncology and ADC target, which is overexpressed across a range of solid tumors, and is often associated with a poor clinical outcome," said David Dornan, Ph.D., Chief Scientific Officer of Elevation Oncology. "At AACR, we plan to share preclinical proof-of-concept data highlighting our progress towards the development of a differentiated HER3-ADC.
StockConsultant
Posted - 03/28/24
$ELEV Elevation Oncology stock bull flag breakout watch , https://stockconsultant.com/?ELEV
Peterpaypaul
Posted - 03/27/24
$ELEV A few big Players (Institutional) are chomping at the bit. This is getting very interesting.... 🤔
RainbowTrump
Posted - 03/27/24
$ELEV started position at $5 today